MA53105A - Activateurs de la réponse à une protéine non dépliée - Google Patents

Activateurs de la réponse à une protéine non dépliée

Info

Publication number
MA53105A
MA53105A MA053105A MA53105A MA53105A MA 53105 A MA53105 A MA 53105A MA 053105 A MA053105 A MA 053105A MA 53105 A MA53105 A MA 53105A MA 53105 A MA53105 A MA 53105A
Authority
MA
Morocco
Prior art keywords
activators
response
unfolded protein
unfolded
protein
Prior art date
Application number
MA053105A
Other languages
English (en)
Inventor
Matthew W Boudreau
Paul J Hergenrother
David J Shapiro
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MA53105A publication Critical patent/MA53105A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA053105A 2018-07-03 2019-07-01 Activateurs de la réponse à une protéine non dépliée MA53105A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862693641P 2018-07-03 2018-07-03

Publications (1)

Publication Number Publication Date
MA53105A true MA53105A (fr) 2021-05-12

Family

ID=69059783

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053105A MA53105A (fr) 2018-07-03 2019-07-01 Activateurs de la réponse à une protéine non dépliée

Country Status (22)

Country Link
US (3) US12180159B2 (fr)
EP (1) EP3817741A4 (fr)
JP (1) JP2021529757A (fr)
KR (1) KR20210027382A (fr)
CN (1) CN112423743A (fr)
AU (1) AU2019299221A1 (fr)
BR (1) BR112020025591A2 (fr)
CA (1) CA3103958A1 (fr)
CL (1) CL2020003423A1 (fr)
CO (1) CO2020016690A2 (fr)
CR (1) CR20210060A (fr)
DO (1) DOP2020000256A (fr)
EA (1) EA202190146A1 (fr)
EC (1) ECSP20084330A (fr)
IL (1) IL279429A (fr)
JO (1) JOP20200344A1 (fr)
MA (1) MA53105A (fr)
MX (1) MX2021000043A (fr)
PE (1) PE20210662A1 (fr)
PH (1) PH12020552223A1 (fr)
SG (1) SG11202012902WA (fr)
WO (1) WO2020009958A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529757A (ja) 2018-07-03 2021-11-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 小胞体ストレス応答の活性剤
WO2021222738A1 (fr) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Composés pour cancers positifs au récepteur des oestrogènes
WO2022020605A1 (fr) * 2020-07-23 2022-01-27 The Board Of Trustees Of The University Of Illinois Traitement du cancer du sein positif aux récepteurs des œstrogènes metastasé
WO2022032146A1 (fr) * 2020-08-07 2022-02-10 Systems Oncology, Llc Procédés d'inhibition de la croissance de cancers era positifs
JP2023546584A (ja) * 2020-10-23 2023-11-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ Ｅｒ陽性がんに選択的な抗がん化合物
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078394A1 (fr) 2002-03-15 2003-09-25 Eli Lilly And Company Derives de dihydroindol-2-one modulant le recepteur nucleaire de l'hormone steroide
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
JP4989976B2 (ja) 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US20070299102A1 (en) 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
BRPI0616459A2 (pt) 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
PE20080655A1 (es) 2006-08-24 2008-07-14 Wyeth Corp Proceso para preparar derivados de indolinona fenilaminopropanol
WO2008071387A1 (fr) * 2006-12-11 2008-06-19 Topotarget A/S Pro-médicaments de composés diphényl ox-indol-2-one pour le traitement de cancers
JP2010525024A (ja) 2007-04-24 2010-07-22 トポターゲット・アクティーゼルスカブ 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
WO2010109008A1 (fr) 2009-03-26 2010-09-30 Topotarget A/S Promédicaments de 3-(4-hydroxyphényl)-indolin-2-ones substitués
WO2014047437A1 (fr) 2012-09-20 2014-03-27 President And Fellows Of Harvard College Oxindoles 3,3-di-substitués en tant qu'inhibiteurs de l'initiation de la traduction
US9316631B1 (en) 2012-10-19 2016-04-19 Whitehead Institute For Biomedical Research ER-stress inducing compounds and methods of use thereof
CA2898732A1 (fr) 2013-01-18 2014-07-24 Mao CHENGJIAN Inhibiteurs d'un recepteur des ƒstrogenes
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
JP2021529757A (ja) 2018-07-03 2021-11-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 小胞体ストレス応答の活性剤

Also Published As

Publication number Publication date
BR112020025591A2 (pt) 2021-03-23
US11584718B2 (en) 2023-02-21
MX2021000043A (es) 2021-03-25
CL2020003423A1 (es) 2021-05-14
AU2019299221A1 (en) 2021-02-04
IL279429A (en) 2021-01-31
JOP20200344A1 (ar) 2020-12-31
EP3817741A4 (fr) 2022-07-06
CA3103958A1 (fr) 2020-01-09
DOP2020000256A (es) 2021-03-15
US12180159B2 (en) 2024-12-31
KR20210027382A (ko) 2021-03-10
US20210276951A1 (en) 2021-09-09
CO2020016690A2 (es) 2021-01-18
US11046647B2 (en) 2021-06-29
JP2021529757A (ja) 2021-11-04
SG11202012902WA (en) 2021-01-28
US20210340100A1 (en) 2021-11-04
WO2020009958A1 (fr) 2020-01-09
CR20210060A (es) 2021-04-08
EP3817741A1 (fr) 2021-05-12
PH12020552223A1 (en) 2021-06-28
US20200190029A1 (en) 2020-06-18
ECSP20084330A (es) 2021-01-29
PE20210662A1 (es) 2021-03-31
CN112423743A (zh) 2021-02-26
EA202190146A1 (ru) 2021-04-27

Similar Documents

Publication Publication Date Title
MA53105A (fr) Activateurs de la réponse à une protéine non dépliée
IL282775A (en) Selection of improved tumor reactive t-cells
EP3571930C0 (fr) Isolat de proteines de pois
DK3584189T3 (da) Fastgjort bindeledslåg
EP3898698A4 (fr) Anticorps spécifiques à muc18
PT3649151T (pt) Proteínas de suporte
MA46180A (fr) Analogues de l'amyline
MA43987A (fr) Détermination de la pureté de protéine multimère
EP3512567A4 (fr) Expression spécifique à une cellule d'arnmod
EP3314503A4 (fr) Simulation d'une application
PT3645518T (pt) Síntese de omecamtiv mecarbil
EP3746081A4 (fr) Nouvelles utilisations
IL268731A (en) New uses of anti-sirpg antibodies
EP3592371A4 (fr) Compositions cannabinoïdes stabilisées, liées à une protéine
HUE064240T2 (hu) Fehérjetisztítás
EP3735420A4 (fr) Protéines de fusion anticorps-cytosine désaminase à domaine unique
EP3728260A4 (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3436049A4 (fr) Protéine 8 de type angiopoïétine (angptl8)
DK3737402T5 (da) Modificeret protein
IL282813A (en) Antibody formulation
EP3752001A4 (fr) Dérivés de sobétirome
EP3574304A4 (fr) Mesures d'interactions protéine-protéine au niveau d'une molécule unique
EP3893658C0 (fr) Isolat de protéine à faible teneur en sodium
EP3898964A4 (fr) Anticorps spécifiques à muc18
IL257887A (en) Expression of fc-containing proteins